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CLASSIFICATION 
From the standpoint of practical therapeutics, four kinds of hypertension in 
1. Arteriosclerotic, associated with arteriosclerosis of the large vessels. 
This is manifested by a wide pulse pressure and usually has a benign prognosis. 
Treatment is symptomatic only : salt restriction or mild depressor agents often 
dramatically relieve symptoms without great effect on the blood pressure. 
2. “Malignant” hypertension as manifested by rapidly rising blood pressure, 
papilledema, retinal hemorrhages and exudates, and renal damage. 
This complication of hypertensive disease is rare in the elderly. As pointed 
out by Perera (l), it may be the clue to a Goldblatt type of hypertension, with 
one kidney involved by an arteriosclerotic plaque or, as we have seen recently, 
by a slowly progressing ureteral obstruction such as that caused by carcinoma 
or irradiation fibrosis. 
the elderly should be distinguished : 
3. “Essential” hypertension with onset after the age of 50. 
It is most unusual, as Perera has emphasized, for hypertension to begin after 
the age of 40. It is probable that hypertension with so late an inception will 
remain benign. This type is easily confused with the arteriosclerotic variety 
and is to be identified by a relatively smaller pulse pressure and a diastolic 
blood pressure usually over 110. It needs no treatment, unless for symptoms or 
for vascular complications. 
4. “Essential” hypertension with onset in middle life and extending into the 
later years. 
When this variety is identified by a specific history, the prognosis for the 
individual is largely based upon the magnitude of vascular disease in the heart, 
(by teleoroentgenogram and electrocardiogram), kidneys (urine albumin, phenol- 
sulfonphthalein, urea or creatinine clearance), and cerebral vessels (history or 
signs of “strokes,” vasospastic episodes, or diffuse cerebral degeneration). If 
these findings are normal, and particularly if the patient is an obese female, the 
prognosis appears excellent, almost regardless of the high blood pressure. How- 
ever, in cases with sustained high pressures, a cerebral hemorrhage may occur 
without warning. If any complications are present, treatment is justified, but 
the choice of drug will depend upon the age and general status of the patient. 
Drastic measures are to be avoided. 
TREATMENT 
Treatment may take several forms such as dietary, surgical or phamnaceutical. 
Salt should be restricted to the 200 mg. level for a trial period of three months, 
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during which blood pressure, salt excretion and symptomatology are checked 
on fortnightly visits to the physician. If improvement does not occur a t  the end 
of this time, the diet may be gradually abandoned. If the blood pressure falls or 
symptoms such as headache, dizziness, angina, dyspnea or edema are relieved, 
the diet is gradually modified upward to the 500-800 mg. level. The usual ex- 
perience of a patient on the low-salt diet is that lassitude and weight loss occur 
during a period of from three to four weeks, followed by stabilization and an 
improved sense of well-being. Consequently, a t  the end of the trial period, many 
patients refuse to return to a free salt intake, because they feel better without 
it. Unfortunately, reduction in blood pressure of significant degree is infre- 
quently observed, but the symptomatic relief and the alleviation or postpone- 
ment of cardiac symptoms seems to justify this management in most elderly 
hypertensive subjects. In my experience, cases of excessive sodium loss associated 
with the “low-salt syndrome” are rarely encountered, although elderly patients 
with renal function less than 50 per cent of normal may occasionally get into 
difficulty during such a rigid salt restriction. If further measures, such as diuretics 
or resins are prescribed for elderly hypertensive individuals without edema, 
serious derangements may occur. 
Sympathectomy has in general been considered inapplicable to the elderly 
hypertensive patient but, in my opinion, certain cases clearly benefit. The ex- 
pectation of significant reduction in blood pressure is a t  least as good as in the 
younger subjects (2) and significant symptomatic relief may also occur. In most 
instances, less drastic methods will prove satisfactory in the elderly, in whom our 
therapeutic objective should not be normalization of the blood pressure but 
rather relief of symptoms and reduction to reasonable levels, in order to avoid 
or lessen the complications of the disease. 
Drug treatment of hypertensive disease is still in the exploratory stage. 
Table 1 illustrates the present choice of therapeutic agents. RauwolJia serpentina 
derivatives are only mildly effective but some of their side effects may be par- 
ticularly useful in the management of the elderly (3). Hydrazinophthalazine 
hydrochloride (hydralazine) (Apresoline) is an excitatory drug which greatly 
increases the circulation (4). It should be employed cautiously in cardiac pa- 
tients. Hexamethonium chloride (5) and Veratrum viride (Protoveratrine) deriva- 
tives (6)  are potent and should be used with great caution in the elderly. 
Since hypertensive disease varies widely, an attempt will now be made to 
relate the treatment to various types of hypertensive disease in the elderly, 
as follows: 
1. Blood pressure usually below 200 systolic; no complications 
2.  Blood pressure usually over 200 systolic; m complications 
No treatment necessary. 
Treatment here is elective, depending upon the patient’s age and cooperation. 
These individuals run the risk of cerebral hemorrhage at  any time, but if in 
good condition and cooperative, they deserve a trial of therapy, in this order: 
1) Sodium restriction, 2) Rauwolfia, 3) Apresoline. 
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3. Blood pressure moderately elevated; symptoms or complications present 
a. Angina. Salt restriction is frequently beneficial and, together with the 
accepted coronary vasodilators, is the treatment of first choice. In  our hands 
the sedative and bradycardiac effects of Rauwolfia are sometimes helpful 
in managing angina pectoris. The tendency to obesity must be controlled, 
however. Oral hexamethonium is to be tried cautiously in order to avoid 
steep falls in blood pressure with the risk of precipitating coronary thrombo- 
sis. Moderate reduction in blood pressure often seems to relieve pain. 
Apresoline is contraindicated. Protoveratrine may be helpful. 
b. Congestive failure. Conventional methods should be tried first, with empha- 
sis on salt restriction (200-mg. sodium diet). If the blood pressure remains 
high and dyspnea or edema recur, hexamethonium should be used to 
control the daytime (ambulatory) blood pressure. Protoveratrine, if neces- 
sary, should be taken nightly for control of paroxysmal dyspnea. Hexa- 
methonium must be used cautiously, as it may produce cumulative toxic 
effects in the face of the renal insufficiency which commonly accompanies 
congestive failure. Rauwolfia may help, especially if tachycardia is per- 
sistent, but it cannot be expected to lower the blood pressure markedly in 
most cases. Apresoline is probably contraindicated. 
c .  Cerebral thrombosis. Apresoline is theoretically the drug which is the most 
likely to improve cerebral blood flow. Despite this, I have seen thromboses 
occur in 3 patients taking Apresoline, without significant reduction in blood 
pressure. Measurements of the effect of the drug on cerebral resistance 
show only slight improvement (4). Consequently the choice of Apresoline 
for the treatment of cerebral thrombosis is not made with great conviction. 
Hexamethonium and Protoveratrine may lower the blood pressure too 
sharply and extend the thrombosis. Rauwolfia is probably not effective. 
Since reductions in pressure without concomitant cerebral vasodilation in 
an elderly person are likely to produce adverse effects, patients who have 
had thrombotic accidents as the only complication of hypertension should 
not be treated wtih depressor drugs. 
d .  Cerebral hemorrhage. The dramatic manifestations of this complication 
theoretically call for acute reduction in blood pressure. In  practice, how- 
ever, control of blood pressure during such an episode is difficult. Hexa- 
methonium has acute effects but when the intracranial pressure is increased 
from bleeding, patients are extremely sensitive and may respond with 
severe hypotension. The drug should be given at  a rate of 0.5 mg. per min- 
ute intravenously, with the patient in the sitting position and the blood 
pressure recorded every thirty seconds. Arfonad, a new vasodepressor, 
may prove more useful in such emergencies, as its effects are more transient 
and hence more controllable (7). When a patient presents himself with the 
residual effects of an old cerebral hemorrhage, a difficult therapeutic de- 
cision has to be made. In general, only symptomatic treatment is advised, 
because hypotensive therapy may precipitate a thrombosis; on the other 
hand, lack of hypotensive therapy may result in a hemorrhage. If the blood 
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pressure is usually over 200, moderate measures of treatment, such as salt 
restriction, Rauwolfia, Apresoline or even hexamethonium and Proto- 
veratrine may be tried, provided the patient’s general condition is good. 
Otherwise, it is best to avoid hypotensive drugs. 
e .  Hypertensive encephahpathy. By this term is meant the acute focal or 
generalized neurologic disturbances produced by severe hypertension in 
the absence of uremia or of chronic cerebral arteriosclerosis. When the 
latter complications can be ruled out, vigorous therapy is often dramatically 
effective in restoring consciousness and clearing residual neurologic symp- 
toms. Hexamethonium should be given intravenously very slowly, as de- 
scribed previously, until the blood pressure is lowered to 170-180 systolic. 
f. Renal complications. Azotemia contraindicates almost all definitive drug 
therapy, because the prognosis is nearly hopeless anyway and vttsodepres- 
sion may lead to rapid progression of the uremia. There are two excep- 
tions: 1) When the azotemia is pre-renal (i.e., cardiac, or due to dehydra- 
tion) and responds to appropriate treatment, and 2) when other symptoms 
demand attention regardless of the renal status (i.e., convulsions, impending 
blindness from retinopathy, or refractory left ventricular failure). In the 
former instance hexamethonium should be very cautiously administered 
by subcutaneous injection beginning a t  5 mg. every four to six hours and 
increasing by 5 mg. per dose until the blood pressure is lowered to a reason- 
able level. During this time, daily creatinine or blood urea determinations 
will indicate whether the uremia is improving or not. If not, treatment 
should be stopped immediately. Ileus, which may come on abruptly due 
to deficient renal removal of hexamethonium, is likewise a calculated risk 
in thia situation. In  the second instance, when uremia is clearly present, 
Protoveratrine or Apresoline is the treatment of choice. We favor the former 
in this situation, because the effect of Apresoline is often unpredictable. 
Considerable symptomatic relief may sometimes be achieved. 
SUMMARY 
The types of hypertension encountered in the elderly are described. Emphasis 
in treatment should be upon milder measures such as salt restriction, Rauwolfia 
derivatives and occasionally hydralazine. More vigorous methods such aa 
sympathectomy, and the administration of hexamethonium chloride or Veratrum 
derivatives should only rarely be used. 
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